Data from noncomparative multicenter trials of
cefoperazone sodium in 17 countries throughout Australasia, Europe, and Latin America were analyzed. The study populations included 1,659 adults and 438 children with a wide variety of serious
urinary tract infections,
respiratory tract infections, and miscellaneous
infections. Most adult patients received either 1 g (42%) or 2 g (53%) of
cefoperazone iv twice daily for 8-10 days. Satisfactory clinical responses were achieved in 91% of 586 assessable patients with
respiratory tract infections, 94% of 571 with
urinary tract infections, and 93% of 301 with miscellaneous
infections. Organisms resistant to most
cephalosporins, including Pseudomonas aeruginosa, other Pseudomonas species, Enterobacter,
indole-positive Proteus, Serratia, Bacteroides fragilis, and Streptococcus faecalis (nonendocarditis
infections) responded to
cefoperazone treatment. Ten percent of patients reported one or more adverse effects directly attributable to
cefoperazone, most of which were mild or moderate in severity. In a global evaluation that took into account baseline disease severity, clinical and bacteriological outcome, and toleration, investigators judged
cefoperazone as excellent or good in 83% of patients, fair in 10%, and poor in 7%. The usual dosage for pediatric patients was 25-50 mg/kg two or three times daily for about seven days. Overall clinical effectiveness in 417 assessable patients was 89% for a wide variety of
infections. Ten of 11 cases of
meningitis were cured. Mild adverse reactions were reported for 14 patients. The results indicate that
cefoperazone sodium is a safe and effective
antibiotic for use in adults and children with serious
bacterial infections.